click below
click below
Normal Size Small Size show me how
Block 2.3
Day 1: Dr. Riccio Hemostasis & Antithrombitics
Question | Answer |
---|---|
What is the process of hemostasis? | 1.) Vasoconstriction 2.) Platelet adhesion, activation, & aggregation = plug 3.) Clotting cascade activation = fibrin clot 4.) Dissolution of clot, fibrinolysis |
T/F In a healthy vessel wall, goal is to promote vasodilation. | T |
What is composed inside the endothelial lining of a healthy vessel wall? | Nitric oxide (NO), Prostacyclin, and Adenosine diphosphatase (ADPase) |
T/F In an injured vessel wall, goal is to promote vasoconstriction. | T |
What is composed inside the subendothelial matrix of an injured vessel wall? | Endothelin, exposed collagen, vWF, fibrinogen, and tissue factor |
What happens during platelet plug formation? | 1. Adhesion (GP1a to collagen, GP1b to vWF to collagen) 2. Activation (Conformational change to express GP2b/3a, degranulation of vesicles, release of thromboxane-A2 (TXA2)) 3. Aggregation (GP2b/3a to fibrinogen to GP 2b/3a, GP 2b/3a to vWF to GP 2b/3a) |
What happens during the activation phase during platelet plug formation? | Recruitment of platelets, conformational change, degranulation of vesicles, and release of TXA2 |
What happens during the aggregation phase during platelet plug formation? | Platelets binding together to form plug |
What antiplatelet medications block ACTIVATION? | Anti-thromboxane (Aspirin) ADP Receptor Antag (thienopyridines: ticlopidine(Ticlid), clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta)) PDE inhibitor (dipyridamole (Persantine), cilostazol (pletal)) Combo (dipyridamole ER/ASA (Aggrenox)) |
What antiplatelet medications block AGGREGATION? | GP2b/3a antagonist (abciximab (ReoPro), eptifibatide (Integrilin), tirofiban (Aggrastat)) |
What is ASA? MOA? Administration? Who should avoid? ADRs? | Aspirin, irreversible COX inhibitor, DO NOT CRUSH EC tabs, with food or full glass of water to minimize GI distress, for AMI, pt chew tab. AVOID pts under 16, pts who are preg or breastfeeding. ADRs: GI discomfort, bronchospasm, tinnitus, rash, bleeding |
What are Thienopyridines? MOA? | ticlopidine(Ticlid), clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta). IRREVERSIBLE bind to P2Y12 receptor. |
What are the BBWs for each Thienopyridine med? | Ticlid: neutropenia/agranulocytosis, TTP, and aplastic anemia (CBC q2 wks) Plavix: alt treatment for CYP2C19 poor metabolizers. Effient: C/I in pts >75 YO, less than 60 kg (consider 5mg daily), history of CVA, active or patho bleeding, thromoboctyopenia |
What is Brilinta? MOA? BBW? | ticagrelor, cyclopentyltriazolopyramidine, REVERSIBLY binds to P2Y12 receptor. BBW: caution bleeding risk and concomitant use of ASA > 100mg will decrease efficacy |
What are GP2b/3a receptor antagonists? MOA? | abciximab (ReoPro), eptifibatide (Integrilin), tirofiban (Aggrastat)), blocks GP2b/3a receptors which decreases adhesion and aggregation |
What are PDE inhibitors? MOA? | dipyridamole (Persantine), dipyridamole ER/ASA (Aggrenox), cilostazol (pletal), inhibits PDE activity within the platelet, increasing cAMP & GMP, therefore decreasing platelet activation |
What promotes the clotting cascade? | Thrombin (LOW concentrations) and Xa (feedback activates VII) |
What inhibitors the clotting cascade? | 1.Thrombin (HIGH concentrations), complexes with thrombomodulin to active Protein C, Protein C & S with APC complex deactivates Va and VIIIa. 2. Antithrombin III: irreversibly binds 2a,9a,10a,11a, and 12a |
What factors does VKA block the formation of? | 2,7,9,10 and Protein C & S |
What factors do DTI block the formation of? | 2a (thrombin) directly |
What factors do Anti-FXa block the formation of? | 10a directly |
What factors do UFH-ATIII block the formation of? | 10a, 2a and Intrinsic factor pathway |
What factors do LMWH-ATIII block the formation of? | 10a and 2a, more selective for 10a |
What factors do Synth. Pentasac-ATIII block the formation of? | Selective for 10a only. |
T/F UFH is safe for pregnancy and lactation patients | T |
What is the dosing for VTE prophylaxis of UFH? | 5000 units SC q8-12hrs |
What is the dosing for VTE treatment of UFH? | 80 units/kg IV bolus, then 18 units/kg/hr CIVI |
What is the dosing for Afib treatment of UFH? | 333 units/kg SC bolus, then 250 units/kg SC q8 hr |
What do we use to monitor UFH? What is the therapeutic range? | aPPT or PTT , Therapeutic range: 1.5-2.5 x normal aPTT Anti-factor Xa level therapeutic range: 0.3 - 0.7 IU/mL ACT: bedside |
What are the ADRs and Drug interactions of UFH? | Bleeding, HIT/HAT, and osteoporosis with chronic use. D/I: antiplatelet, anticoagulant, fibrinolytic, NSAIDS |
T/F LMWH is safe in pregnancy (NOT during labor/delivery) | T |
What is the dosing for VTE prophylaxis of Lovenox? | 40 mg SC daily 30 mg SC q12 hr (Orthopedic surgery ONLY) Renal: CrCl <30 ml/min: 30 mg SC daily |
What is the dosing for VTE/ACS treatment of Lovenox? | 1 mg/kg SC q12 hr 1.5 mg/kg SC daily Renal: Crcl <30 ml/min: 1 mg/kg SC daily |
How do we monitor LMWH? | Renal function (SCr), platelet count, and Anti-factor Xa( not routinely recommended, may be useful in pregnancy, renal impairment, obese patients. |
What is the therapeutic level for LMWH using Anti-Factor Xa? | >1 unit |
What are the ADRs, D/I and BBW with LMWH? | Bleeding, lower rates of HIT than UFH. D/I: antiplatelet, anticoagulant, fibrinolytic, NSAIDS. BBW: hematoma risk with epidural/spinal puncture |
What is the reversal agent for heparin products? | Protamine |
How do we dose Protamine on patients who overdose on UFH? | 100 units UFH = within 30 mins, 1 mg protamine. within 30-120 min, 0.5 mg protamine. >120 min, 0.25 mg protamine. |
How do we dose Protamine on patients who overdose on LMWH? | 1 mg enoxaparin, 100 units dalteparin, 100 units tinzaparin= within 8 hrs, 1mg protamine. 8-12hr, 0.5mg protamine. >12 hr, do no use. |
What is the dosing for VTE prophylaxis of Arixtra? | 2.5mg SC daily |
What is the dosing for VTE treatment of Arixtra? | <50kg: 5mg SC daily. 50-100kg: 7.5 mg SC daily, >100kg: 10mg SC daily. Renal: CrCl 30-50ml/min: decrease dose 50%, if <30: do NOT use |
How do we monitor Arixtra? ADRs? D/I? Half-life? | SCr and sign/symptoms of bleeding. Bleeding but no reports of HIT. D/I: antiplatelet, anticoagulant, fibrinolytic, NSAIDs. Half life: 17-21hrs |
What is the MOA of rivaroxaban & edoxaban? | binds directly to FREE F10a |
What is the MOA of apixaban? | Binds directly to free and clot bound F10a |
T/F Xarelto should be taken with food at higher dosing (>15mg). | T |
T/F Xarelto has CYP and P-gp substrate interactions. | T |
What is the dosing for VTE prophylaxis of Xarelto? | 10 mg PO daily, if CrCl is 15-30 ml/min: caution, if <15 ml/min: AVOID use. |
What is the dosing for VTE treatment of Xarelto? | 15mg PO BID with food for 21 days, then 20 mg PO daily with food thereafter. 10mg daily may be considered beyond 6 months |
What are counseling points for Xarelto? | may chew/crush, doses >15mg require large meal intake, missed dose can be taken same day for max dose of 30 mg PO for VTE ONLY, hold dosing 24 hours prior to surgery or invasive procedures |
T/F Eliquis has CYP and P-gp substrate interactions | T |
What is the dosing for VTE prophylaxis of Eliquis? | 2.5mg PO BID |
What is the dosing for VTE treatment of Eliquis? | 10 mg PO BID for 7 days, then 5 mg PO BID, extended duration: 2.5mg BID |
T/F Eliquis should be AVOIDED in pts taking strong CYP3A4 & P-gp inhibitors | T |
What are counseling points for Eliquis? | NG tube: may crush or chew & mixed with 60 mL D5W, with or without food, no double dosing if missed dose, hold dosing 48 hours prior to moderate or high risk of bleeding surgery or invasive procedures; hold 24 hours with mild/low bleed risk |
T/F Savaysa has only P-gp substrate interactions | T |
What is the dosing for VTE treatment of Savaysa? | 60 mg PO daily after 5 days-10 days of parental anticoagulant. < 60kg or CrCl 15-50ml/min = 30 mg daily. |
How do we monitor Savaysa? | SCr |
What are some counseling points of Savaysa? | take with or without food, missed doses may be taken if >6 hours before next dose, hold dosing 24 hours prior to surgery or invasive. |
Continued on Day 2 slide deck |